beta blockers and semaglutide Wegovy Slashes the Risk of Heart Attack Stroke in a Landmark Trial Afraid of heart failure? Don't

Right heart catheterization is necessary to confirm the diagnosis of PH

*Correspondence: Na Ren, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Furthermore, although concomitant medications changed minimally between the baseline visit and week 40, potential differences in adherence to glucose-lowering, lipid-lowering and antihypertensive therapies during the trial may have influenced the achievement of therapeutic targets and, consequently, the interpretation of our findings

For example, participants in STEP 1 who combined Wegovy with lifestyle changes lost an average of 14.9% of their baseline body weight over 68 weeks, significantly more than the placebo group, which saw only a 2.4% reduction

In the Phase 2 trial, participants on retatrutide showed significant reductions in hepatic fat content, with some achieving near-complete resolution of metabolic associated steatotic liver disease

One of the most common questions facing patients today is the delivery method: should you opt for the Wegovy pill or the weekly injection